MSK’s David Hyman and Peter Bach were interviewed by The New York Times about two revolutionary treatment strategies, immunotherapy and personalised medicine, and a problem that few would have predicted several years ago. There are not enough patients available to conduct the trials, the New York Times reports, something the newspaper describes as possibly being “unprecedented” in medical research. There are currently about 1,000 immunotherapy drug trials, and that number’s expected to grow. Peter Bach told the Times that “we are squandering our most precious resource—patients.”